AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$CRSP

Behbahani Ali sold $781K of CRSP

Behbahani Ali sold 13,679 shares of CRISPR Therapeutics AG (CRSP) at $57.09 ($0.78M total) on 2026-09-17.

Original reporting
SEC EDGAR · Behbahani Ali
Published Sep 21, 2026, 10:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 12:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRSP
Bearish
medium confidence
Mentioned
$CRSP
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted as a negative signal by the market.

02

Market read

Insider sales are closely watched; this modest sale may cause slight short-term price movement.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: post-market filing on Sep 21, 2026

Background

SEC Form 4 filings disclose insider transactions. This filing reports a director's sale of CRISPR Therapeutics shares.

Company-level read

Ticker impact

$CRSPBearishMedium confidence
Context

Director Behbahani Ali sold 13,679 shares of CRISPR Therapeutics for $781K, reducing his stake to 16,637 shares.

Expected impact

Modest downward pressure over the next few trading sessions.

Evidence & confidence

A $781K sale by a director is a material insider transaction, but the amount is modest relative to market cap, limiting impact.

Market effects

Sector

Minimal; the sale does not affect the broader biotech sector.

Regional

None; the transaction is company-specific.

Global

Low; limited to CRISPR Therapeutics investors.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Company
    CRISPR Therapeutics AG

    Biotech firm developing CRISPR gene-editing therapies.

  • Individual
    Behbahani Ali

    Director of CRISPR Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRSP insider trading history →

Related articles

OCT 28
$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

stocktwits.com2 min
OCT 24
$CRSPMedAI 8/10

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

CRISPR Therapeutics (CRSP) reports promising Phase 1a trial data for CTX310, a gene-editing therapy for high LDL and TG levels, with potential market of 40M+ U.S. patients. The company also shares Casgevy's rights with Vertex (VRTX). CTX310's Phase 1b results are expected in November. CRISPR's pipeline includes other candidates like CTX611, but faces risks of setbacks and market adoption challenges.

finance.yahoo.com3 min